- Conditions
- Platinum-Sensitive Ovarian Cancer in First Relapse
- Interventions
- Farletuzumab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- MORAb-003
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Farletuzumab, Carboplatin, and PLD
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Brightwaters, New York + 2 more
- Conditions
- Resectable, Non-functioning Pituitary Adenoma
- Interventions
- Farletuzumab
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Adenocarcinoma of the Lung
- Interventions
- Farletuzumab, Placebo, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin
- Biological · Other · Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Chandler, Arizona • Glendale, Arizona • Beverly Hills, California + 50 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- MORAb-202
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • Lone Tree, Colorado • Clermont, Florida + 10 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- MORAb-003
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Chula Vista, California • San Antonio, Texas
- Conditions
- Ovarian Cancer
- Interventions
- MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more
- Conditions
- Neoplasms, Ovarian
- Interventions
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Francisco, California • Whittier, California + 7 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Interventions
- Farletuzumab, Chemo Plus Far
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 18
- States / cities
- San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more
- Conditions
- Solid Tumor
- Interventions
- Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more